Form 4: Oric Pharmaceuticals CFO Dominic Piscitelli Granted Stock Options and Restricted Stock Units

Chief Financial Officer of Oric Pharmaceuticals, Dominic Piscitelli, received stock options for 202,500 shares and 34,000 restricted stock units on January 2, 2025.

Summary

• Dominic Piscitelli, the CFO of Oric Pharmaceuticals, was granted stock options and restricted stock units (RSUs) on January 2, 2025.
• The stock options are for 202,500 shares with an exercise price of $8.26.
• 25% of the stock options will vest on January 2, 2026, with the remaining shares vesting monthly over the following three years.
• The RSUs granted total 34,000 shares of common stock.
• One-third of the RSUs will vest annually on December 15, 2025, December 15, 2026, and December 15, 2027.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, suggesting stability and alignment of interests. The sentiment is neutral to positive.

Positives

• The granting of stock options and RSUs to the CFO aligns his interests with those of the shareholders.
• The vesting schedules incentivize long-term performance and retention.

Industry Context

Granting stock options and RSUs is a common practice in the pharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
• Vesting schedules are also typical, designed to retain key personnel and incentivize long-term value creation.

Stakeholder Impact

• Shareholders may view the grant of stock options and RSUs positively as it aligns management's interests with long-term value creation.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates